Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

Current Opinion in Oncology

Volumn 26, Issue 4, 2014, Pages 428-433

  Vormoor, Britta ^a,b   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemosensitization; Ewing sarcoma; PARP inhibitors; Radiosensitization

Indexed keywords

BIOLOGICAL MARKER; BMN 673; BUSULFAN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; E 7449; IRINOTECAN; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; ONCOPROTEIN; RNA BINDING PROTEIN EWS; RUCAPARIB; TEMOZOLOMIDE; TOPOTECAN; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADOLESCENT; ADULT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL SPECIFICITY; CHEMOSENSITIZATION; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DRUG CYTOTOXICITY; ENZYME INHIBITION; EWING SARCOMA; EWING SARCOMA CELL LINE; HUMAN; IONIZING RADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOSENSITIZATION; RECOMBINATION REPAIR; REVIEW; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); PHYSIOLOGY; SARCOMA, EWING;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; SARCOMA, EWING;

EID: 84902266437     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000091     Document Type: Review

References (24)

1. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann Oncol 1998; 9:275-281.
2. Cotteril SJ, Ahrens S, Paulussen M, et al. Prognostic Factors in Ewings Tumour of Bone: Analysis of 975 Patients from the European Intergroup Cooperative Ewings Sarcoma Study Group. JCO 2000; 18:3108-3114.
3. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 2011; 57:549-553.
4. Potratz J, Dirksen U, Jürgens H, Craft A. Ewing sarcoma: clinical state of the art. Pediatr Hematol Oncol 2012; 29:1-11.
5. Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewings sarcoma. Cancer Res 2012; 72:1608-1613.
6. Garnett MJ, Edelman EJ, Heidorn S, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483:570-575.
7. Schreiber V, Dantzer F, Amé JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-528.
8. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301.
9. De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012; 84:137-146.
10. Curtin NJ. PARP and PARP inhibitor Therapeutics. In:Madhusudan S, Wilson D, editors. DNA Repair and Cancer: Bench to Clinic. Enfield, USA: Science Publishers; 2012. (ISBN 978-1-57808-742-6).
11. Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006; 20:1709-1711.
12. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9:5370-5379.
13. Daniel RA, Rozanska AL, Mulligan EA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer 2010; 103:1588-1596.
14. Daniel RA, Rozanska AL, Thomas HD, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009; 15:1241-1249.
15. Plummer R, Jones C,Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917-7923.
16. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutationassociated and BRCA-like malignancies. Ann Oncol 2014; 25:32-40.
17. Brenner JC, Ateeq B, Li Y, et al. Mechanistic rationale for inhibition of poly(ADP-Ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19:664-678.
18. Smith MA, Kang M, Reynolds CP, et al. Pediatric Preclinical Testing Program (PPTP) Evaluation of BMN 673, an inhibitor of Poly-ADP Ribose Polymerase (PARP), alone and with Temozolomide [abstract]. Mol Cancer Ther 2013; 12 (11 Suppl); Abstract nr C206.
19. Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in paediatric solid tumours. Pediatr Blood Cancer 2014; 61:145-150.
20. Vormoor B, Wilkinson S, Harvey F, et al. Ewings sarcoma cells can be sensitized to temozolomide and to a lesser extent to radiotherapy by cotreatment with a PARP-inhibitor (AG014699). Eur J Cancer 2012; 48 (Suppl 6):106-107; abstract nr 349.
21. Wilcoxen KM, Brooks DG, Tiruchinapalli D, et al. The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewings sarcoma tumorgraft models. Mol Cancer Ther 2013; 12 (11 Suppl); Abstract nr A258.
22. Lee HJ, Yoon C, Schmidt B, et al. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther 2013; 12:2591-2600.
23. Choy E, Butrynski J, Harmon D, et al. Translation of preclinical predictive sensitivity of Ewing sarcoma to PARPi: Phase II study of olaparib in adult patients with recurrent/metastatic Ewing sarcoma following failure of prior chemotherapy. Cancer Res 2013; 73 (8 Suppl). doi:10.1158/1538-7445.AM2013- LB-174; Abstract nr LB-174.
24. Wainberg ZA, de Bono JS, Mina L, et al. Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. Mol Cancer Ther 2013; 12 (11 Suppl); Abstract nr C295.